clinical trial · NCT05468489
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech·phase3·active not recruiting·n = 200
Extensive Stage Small Cell Lung CancerSerplulimab + chemotherapy (carboplatin-etoposide)Atezolizumab + chemotherapy (carboplatin-etoposide)
brief summary
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
started
Nov 18, 2022
primary completion
Feb 28, 2026
completion
Dec 31, 2027
last updated
Oct 21, 2025
official title
A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol